When to Treat, How to Use: The Expanding Role of TNF-α Antagonists in Dermatology

A supplement to Skin & Allergy News. This supplement was jointly sponsored by the Office of Continuing Education at the State University of New York (SUNY) Upstate Medical University and Precept Educational Sciences.
SUNY Upstate Medical University and Precept Educational Sciences gratefully acknowledge an educational grant from Abbott Immunology in support of this CME activity.
This CME activity is based on a CME symposium which was held on July 28, 2006, in San Diego, Calif.

•Topics/Faculty
•Target Audience
•Activity Objectives
•Accreditation

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 12.

Topics/Faculty

Getting to the Cause: TNF-α Antagonists in the Treatment of Psoriatic Disorders
Craig Leonardi, MD, Executive Editor
Associate Clinical Professor of Dermatology
Saint Louis University
Central Dermatology
St. Louis, Mo.
Dr Leonardi has received grant/research support from Abbott Laboratories, Amgen Inc., Genentech, Inc., and Centocor, Inc. He is a consultant for and is on the speakers? bureau for Abbott, Amgen, and Genentech.

Improving Outcomes With the Use of TNF-α Antagonists: Assessment of Treatment Safety
Alexa Boer Kimball, MD, MPH
Assistant Professor
Director, Clinical Unit for Research Trials in Skin
Harvard Medical School
Massachusetts General Hospital and Brigham & Women's Hospital
Boston, Mass.
Dr Kimball is a consultant for Procter & Gamble, Warner Chilcott, Amgen, Vanda Pharmaceuticals, TransForm Pharmaceuticals, Inc., MacroChem Corporation, QTL Biosystems, and 3M Pharmaceuticals. She is an investigator for Procter & Gamble, OrthoNeutrogena, Warner Chilcott, Amgen, Centocor, Connetics Corporation, Abbott, 3M, Path Scientific, LLC, Merck & Co., Inc., BioCryst Pharmaceuticals, Inc., NUCRYST Pharmaceuticals Corp., Genmab A/S, and Pepgen Corporation. Dr Kimball is on advisory boards for OrthoNeutrogena, Nu Skin Enterprises, Amgen, Centocor, Connetics, Unilever, and Abbott. She is on the speaker's bureau for Amgen, Centocor, and Abbott.

Optimizing Care: Applying Outcome Data to Clinical Practice
Alan Menter, MD
Chief, Division of Dermatology
Baylor University Medical Center
Dallas, Tex.
Dr Menter has received research support from and/or is a consultant and/or lecturer for Abbott, Amgen, Biogen Idec, Centocor, Genentech, and Serono, Inc.

Target Audience

When to Treat, How to Use: The Expanding Role of TNF-α Antagonists in Dermatology is designed for dermatologists and other health care professionals who treat patients with psoriatic disease.

Activity Objectives

Upon completion of this activity, participants should be able to:

• Examine the clinical features of psoriatic diseases and the role of tumor necrosis factor (TNF)-α in the treatment of these diseases.

• Discuss the most recent psoriasis and psoriatic arthritis (PsA) clinical trial data demonstrating the efficacy and safety of TNF-α antagonists, as well as improvements these therapies bring about in quality of life.

• Focus on important issues critical to the safe use of TNF-α antagonists, such as vaccination during treatment, history of malignancy, pregnancy, combination therapy, a demyelinating disorder, or congestive heart failure.

• Illustrate the evolving role of dermatology health care professionals in the diagnosis, monitoring, and long-term treatment of psoriasis and PsA with TNF-α antagonists.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the SUNY Upstate Medical University and Precept Educational Sciences. SUNY Upstate Medical University is accredited by the ACCME to provide continuing medical education (CME) for physicians.

SUNY Upstate Medical University designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in this activity.

Release Date of Activity: November 1, 2006
Expiration Date of Activity: November 1, 2007

Copyright © 2006 Elsevier Inc.

---